EUCTR2010-021569-58-FI进行中（未招募）不适用
A phase I/II, double-blind, randomized, multicentre study to evaluate the safety and immunogenicity of new formulations of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib vaccine when administered to healthy infants as a primary vaccination course at 2, 3 and 4 months of age. - DTPA-HBV-IPV-124 PRI
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 720
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- A male or female between, and including, 60 and 90 days of age at the time of the first vaccination.
- •- Born after a gestation period of 37 to 42 weeks inclusive.
- •- Subjects who the investigator believes that their parent(s)/LAR(s) can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits).
- •- Written informed consent obtained from the parent(s)/LAR(s) of the subject.
- •- Healthy subjects as established by medical history and clinical examination before entering into the study.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 720
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Child in care.
- •-Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- •-Chronic administration (defined as more than 14 days in total) of
- •immunosuppressants or other immune-modifying drugs since birth. For
- •corticosteroids, this will mean prednisone = 0.5 mg/kg/day, or equivalent. Inhaled and topical steroids are allowed.
- •-Administration of a vaccine not foreseen by the study protocol, within 30 days prior to the first study visit, or planned administration during the study period, with the exception of oral rotavirus vaccination which is allowed at any time during the study.
- •-Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
- •-Evidence of previous or intercurrent diphtheria, tetanus, pertussis, polio, hepatitis B, Hib and/or pneumococcal vaccination or disease, with the exception of hepatitis B vaccination at birth.
- •-Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
- •-Family history of congenital or hereditary immunodeficiency.
- •-History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine(s).
- •-Major congenital defects or serious chronic illness.
- •-History of any neurological disorders or seizures.
- •-Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
- •-Acute disease and/or fever at the time of enrolment.
- •Acute disease is defined as the presence of a moderate or severe illness with or without fever.
- •-Fever is defined as temperature = 37.5°C on axillary, oral or tympanic setting, or = 38.0°C on rectal setting. The preferred route for recording temperature in this study will be axillary or rectal.
- •-Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may be enrolled at the discretion of the investigator.
研究者
相似试验
进行中（未招募）
1 期
A Phase I/II randomised, double-blind, multi-centre study to assess the efficacy of AZD2281 when given in combination with paclitaxel in the 1st or 2nd line treatment of patients with metastatic Triple Negative Breast CancerMetastatic Triple Negative Breast CancerMedDRA version: 9.1Level: LLTClassification code 10055113Term: Breast cancer metastaticEUCTR2008-002608-25-ATAstraZeneca AB260
进行中（未招募）
1 期
A Phase I/II randomised, double-blind, multi-centre study to assess the efficacy of AZD2281 when given in combination with paclitaxel in the 1st or 2nd line treatment of patients with metastatic Triple Negative Breast CancerMetastatic Triple Negative Breast CancerMedDRA version: 9.1Level: LLTClassification code 10055113Term: Breast cancer metastaticEUCTR2008-002608-25-DKAstraZeneca AB270
进行中（未招募）
1 期
A Phase I/II randomised, double-blind, multi-centre study to assess the efficacy of AZD2281 when given in combination with paclitaxel in the 1st or 2nd line treatment of patients with metastatic Triple Negative Breast CancerEUCTR2008-002608-25-BEAstraZeneca AB270
进行中（未招募）
1 期
A Phase I/II randomised, double-blind, multi-centre study to assess the efficacy of AZD2281 when given in combination with paclitaxel in the 1st or 2nd line treatment of patients with metastatic Triple Negative Breast CancerMetastatic Triple Negative Breast CancerMedDRA version: 9.1Level: LLTClassification code 10055113Term: Breast cancer metastaticEUCTR2008-002608-25-CZAstraZeneca AB19
进行中（未招募）
不适用
Dose finding clinical study, multicentre, with allergy vaccines for patients allergic to Phleum pratense pollen at different doses and placebo, a substance with inactive ingredients of medicine and whose appearance is identical to that of the actual treatment in question.EUCTR2011-000814-21-PTBIAL INDUSTRIAL FARMACEUTICA, S.A.150